Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice

Future Oncology · Published 2026-06-09 · DOI 10.1080/14796694.2026.2676559

Free full text

Authors (2)

Stephen J. Freedland, Ugo De Giorgi

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Freedland, S., Giorgi, U. (2026). Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice. Future Oncology. https://doi.org/10.1080/14796694.2026.2676559

Related articles

• Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study · Future Oncology · 2026 · Same journal
• Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences · Future Oncology · 2026 · Same journal
• Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary · Future Oncology · 2026 · Same journal
• Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience · Future Oncology · 2026 · Same journal
• IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma · Future Oncology · 2026 · Same journal
• Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia · Future Oncology · 2026 · Same journal
• Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions · Future Oncology · 2026 · Same journal
• A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer · Future Oncology · 2026 · Same journal
• Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary · Future Oncology · 2026 · Same journal
• A Naples prognostic score-based nomogram enhances perioperative risk stratification for resected pancreatic cancer · Future Oncology · 2026 · Same journal